Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
Learn how Immuno-STAT Biologics selectively modulate disease-associated T cells to fight cancer.
Mar 16 | 2021
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Mar 15 | 2021